Literature DB >> 25806183

Combined treatment with MET inhibitors and other therapies in lung cancer.

Rakesh Bagai1, Patrick C Ma2.   

Abstract

Entities:  

Year:  2012        PMID： 25806183      PMCID： PMC4367561          DOI： 10.3978/j.issn.2218-6751.2012.09.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  20 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.

Authors:  Giorgio V Scagliotti; Silvia Novello; Joan H Schiller; Vera Hirsh; Lecia V Sequist; Jean-Charles Soria; Joachim von Pawel; Brian Schwartz; Reinhard Von Roemeling; Alan B Sandler
Journal:  Clin Lung Cancer       Date:  2012-03-21       Impact factor: 4.785

Review 3.  Targeting the c-Met signaling pathway in cancer.

Authors:  Benedetta Peruzzi; Donald P Bottaro
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

4.  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Joachim von Pawel; Edward G Garmey; Wallace L Akerley; Wolfram Brugger; Dora Ferrari; Yinpu Chen; Daniel B Costa; David E Gerber; Sergey Orlov; Rodryg Ramlau; Susan Arthur; Igor Gorbachevsky; Brian Schwartz; Joan H Schiller
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

Review 5.  MET signaling: novel targeted inhibition and its clinical development in lung cancer.

Authors:  Yan Feng; Praveena S Thiagarajan; Patrick C Ma
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

6.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors:  Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

Review 7.  Circumventing cancer drug resistance in the era of personalized medicine.

Authors:  Levi A Garraway; Pasi A Jänne
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

8.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

9.  Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.

Authors:  Luping Lin; Trever G Bivona
Journal:  Chemother Res Pract       Date:  2012-08-29

10.  Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

Authors:  Z Tang; R Du; S Jiang; C Wu; D S Barkauskas; J Richey; J Molter; M Lam; C Flask; S Gerson; A Dowlati; L Liu; Z Lee; B Halmos; Y Wang; J A Kern; P C Ma
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640
View more
  1 in total

1.  Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.

Authors:  Ichiro Kawada; Rifat Hasina; Qudsia Arif; Jeffrey Mueller; Erin Smithberger; Aliya N Husain; Everett E Vokes; Ravi Salgia
Journal:  Cancer Res       Date:  2013-12-04       Impact factor: 12.701
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.